Afrezza’s Initial Sales Create Buying Opportunity

After a drug receives FDA approval, shareholders expect significant sales will soon follow. However, since obtaining an FDA approval does not remove all of the obstacles to sales, it is often the case that initial sales fall below expectations and the stock drops accordingly. Afrezza’s launch is about to give us just this kind of opportunity to buy MannKind.Buying high […]